Decoy Therapeutics explores pan-filovirus program via FDA Animal Rule
Decoy Therapeutics said its next-generation D-MAVs showed potent in-vitro activity against Ebola Zaire and Marburg, and that it is exploring a pan-filovirus program using the FDA Animal Rule pathway and non-dilutive funding, targeting potential FDA Priority Review Voucher eligibility.
Decoy Therapeutics, Inc. (NASDAQ:DCOY), a biotechnology company pioneering Designable Molecules Against Viruses, said its next-generation D-MAVs demonstrated potent in vitro activity against Ebola Zaire and Marburg viruses. The company said it is targeting high-value FDA Priority Review Voucher eligibility. The update was dated Sept.
22, 2026.